Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy

Jimm Grimm,a Tamara LaCouture, Raymond Croce, Inhwan Yeo, Yunping Zhu, and Jinyu Xue
Department of Radiation Oncology, Cooper University Hospital, One Cooper Plaza, Camden, NJ, 08103, USA.
Grimm-Jimm@CooperHealth.edu

Received 21 May, 2010; accepted 10 January, 2011

Almost 20 years ago, Emami et al. presented a comprehensive set of dose tolerance limits for normal tissue organs to therapeutic radiation, which has proven essential to the field of radiation oncology. The paradigm of stereotactic body radiotherapy (SBRT) has dramatically different dosing schemes but, to date, there has still been no comprehensive set of SBRT normal organ dose tolerance limits.

As an initial step toward that goal, we performed an extensive review of the literature to compare dose limits utilized and reported in existing publications. The impact on dose tolerance limits of some key aspects of the methods and materials of the various authors is discussed. We have organized a table of 500 dose tolerance limits of normal structures for SBRT. We still observed several dose limits that are unknown or not validated. Data for SBRT dose tolerance limits are still preliminary and further clinical trials and validation are required. This manuscript presents an extensive collection of normal organ dose tolerance limits to facilitate both clinical application and further research.

PACS numbers: 87.53.Ly, 87.55.dk

Key words: dose tolerance limits, adverse events, stereotactic body radiotherapy, radiosurgery, DVH evaluation

I. INTRODUCTION

In a recent journal article, Papiez and Timmerman(1) identified the most important area in which stereotactic body radiotherapy (SBRT) needs to mature to reach its full potential: “The main obstacle for safe application of the SBRT treatment technique is the unavailability of data that allow unambiguous determination of the parameters for fractionation schemes and dose prescriptions.” It is the aim of this review to present updated dose tolerance limits to all critical structures for SBRT fractionation schemes, and to extend the historical data as much as possible, based on recent publications. We consider SBRT to be small, focused, stereotactically accurate radiation treatments with one to five fractions(2) delivered anywhere in the body.

This manuscript represents Phase I of a three-phase project to determine SBRT dose tolerance limits. This first phase is to assemble the range of SBRT dose tolerance limits that have been used clinically and organize them into a format suitable for future research. Some of these dose limits are from randomized trials that have already completed accrual like RTOG 0618, but even in most of those instances, the follow-up data have not yet been published. At the other extreme, some of the published dose tolerance limits are only from a single case study, and some report doses that caused adverse events and should be avoided. Our Phase II effort is to analyze these dose tolerance limits, consolidate them into expert-opinion “high-risk” and “low-risk” categories, and provide dose tolerance limits in a unified framework from one to five

a Corresponding author: Jimm Grimm, Cooper CyberKnife Center, Cooper University Hospital, 715 Fellowship Road, Mt. Laurel, NJ 08054, USA; phone: 856/638-1180; fax: 856/638-1188; email: Grimm-Jimm@CooperHealth.edu
fractions. We are working with many other researchers on the Phase II effort, but we feel that the content of these Phase I dose limits should already be quite useful for research. However, few of these Phase I limits are based on clinical outcome data and these dose tolerance limits have not been validated, so clinical use of them could be hazardous unless the caveats from each publication are heeded. The Phase III effort will be a statistical analysis of long-term multi-institutional follow-up data, to determine the real dose tolerance limits.

The literature already contains a wealth of information regarding the various tumor types treated, as well as the rationale and strategy for defining and delivering radiosurgical treatments. In this manuscript, we avoid what is readily available elsewhere and refer the reader to the literature. Instead, we attempt to aggregate and organize all of the currently-published dose tolerance limits into a single manuscript, and limit the discussion to some of the nuances of those dose tolerance limits. Even with such limited focus, it is still not possible to explain all details of the dose tolerance limits fully, and the reader is still referred to the numerous references to thoroughly understand the background of each dose tolerance limit.

After 20 years of RTOG trials, conventional radiation therapy had progressed to the point where Emami et al.\(^3\) could, with relative certainty, pose the dose tolerance limits in terms of 5% or 50% chance of a specified adverse event occurring within five years. In contrast, the published follow-up data for SBRT are inadequate to reliably determine probability of adverse events. In the meantime, it is important to have a review such as this manuscript that extensively summarizes the dose limits that are currently being used, and to summarize some of the issues regarding those limits.

The simplicity of the Emami limits is that all prescriptions were in 1.8 or 2 Gy fractions. In contrast, SBRT prescription schemes typically range from 5 Gy per fraction up to 20 Gy per fraction or more. In this new radiation delivery paradigm, normal organ dose tolerance limits and the dose-volume response of the tumors depend strongly on the number of fractions used and the dose per fraction. In order to completely fulfill the need that Papiez and Timmerman recommended,\(^1\) it will take years of carefully planned randomized trials to truly determine the optimum prescriptions – clearly beyond the scope of any single manuscript. Until these experiences can be generated, this work attempts to summarize the available dose tolerance limits from the literature and establish some boundaries within which doses can be prescribed.

Several review articles have recently presented a wealth of dose tolerance limits in convenient tabular form.\(^4,5,6,7,8\) As useful as they are, each article only reveals a few dozen dose limits, and the clinical user soon realizes that many needed limits are still missing. This manuscript presents 500 dose tolerance limits, for a broader range of anatomical structures, for relatively more complete coverage of the SBRT fractionation schemes, and to show the variation of limits among many of the leading institutions. In SBRT, the goal is frequently to deliver the highest possible dose to the tumor; hence, we often find ourselves prescribing to meet the dose limits rather than prescribing to the ideal prescription the physician desires. This means a solid understanding of dose tolerance limits is of paramount importance.

Treating an area that had prior radiation is far more complex than the initial treatment. Some of the references address the issue, although most do not. Retreatments are beyond the scope of this manuscript.

The equation for biological effective dose (BED) provides a simple and straightforward way to compare doses from different fractionation schemes.\(^9-13\) It would be possible to simply convert the Emami dose limits to any fractionation scheme using this equation, as was done in.\(^14\) Although these tables are a very important reference tool, they leave out an enormous amount of detail. The response to radiation delivered in one to five fractions could be dramatically different from the response in 25 to 40 fractions – beyond the ability of a simple equation to predict. This type of theoretical analysis is helpful to form the basis for clinical investigations, but by itself has no clinical validation.

Many critics of the work regarding SBRT dose tolerance limits point out limitations that have not even been fully resolved for conventional fractionation. For example, the lower lobes of the
lungs may be more sensitive to radiation pneumonitis than the upper lobes. Another example is the variable time period in which the treatments were delivered – some are daily treatments, others are for every-other-day, or weekly or bi-weekly treatments. These are all important ongoing research topics, but since these effects are still somewhat unknown for conventional radiation, it cannot be expected to be known from the start for SBRT.

We cannot stress emphatically enough that we are not claiming any of the dose limits presented in this work are safe, and we are not claiming that any of them actually are the maximal attainable safe dose. Many clinical trials are still needed to determine the best limits. It is the responsibility of each physician to determine which dose limits are appropriate for their patients.

II. MATERIALS AND METHODS

In a literature review, there is a wide variation of the methods and materials of each cited reference, and it is important for the reader to understand how that variability can affect the presented results. The data presented herein also have a wide variation in validation and reliability. At one extreme, some references are large-scale randomized RTOG trials, and at the other extreme, some of the references are a case study of just a single patient. In nearly all references, the follow-up period is inadequate to assess late effects, but it is still essential to initiate reviews such as this early, to at least see what dose limits other researchers believe are appropriate.

After searching through hundreds of journal articles, we are still missing SBRT dose tolerance limits for many critical structures such as gallbladder, oral mucosa, ovaries, pancreas, parotid, pituitary, spleen, testes, thyroid, ureter, and vagina. There are numerous publications discussing irradiating some of these critical structures when they harbor a malignancy – although it is more challenging to find publications that present dose tolerance limits required to maintain normal function of these organs when they are not the target.

These are not universal dose tolerance limits, and they must be used with an understanding of the treatment scenario for which they were initially developed. For example, dose tolerance limits from the RTOG 7631 trial for palliative whole brain\(^{(15)}\) should not generally be applied to curative cases for children. It is not feasible to enumerate all such possible caveats, and it is the responsibility of the clinical users to study the references and carefully consider which dose limits are appropriate for each patient.

We do not address the issue of medications that could help the patient become more resistant to the effects of radiation, or the issue of medications that could make them more sensitive. For example, if a publication used Ethyol, Zofran, Zantac, Palifermin, Decadron, or some other medication, they could potentially achieve higher dose tolerance limits, but to use those limits safely, the same medications would need to be administered. Conversely, the effects of chemotherapy, molecular targeted agents, Betor, Zevalin, or any other concurrent therapy could potentially make patients more susceptible to complications from radiation, so the dose tolerance limits may need to be lowered in those cases. Many of these effects are known for conventional fractionation schemes, but to fully understand interactions with the extreme hypofractionation schemes of SBRT, many new clinical trials will likely be needed.

III. RESULTS

We report all references that we found to each dose limit in Table 1, regardless of whether each author actually used the dose tolerance limit or not. Some of the higher dose limits of one author might be discussed by other authors who might not actually feel comfortable using a dose that high. It is important to realize that a large number of references for a particular dose tolerance limit could indicate that it is controversial, rather than indicating that it is commonly used.
The second column in the table shows the number of fractions for each dose limit. Some of the tolerance limits are presented in terms of absolute volume in cubic centimeters (cc), while others are presented in terms of percentage of the total volume of the structure. For the absolute volume format, the third column of the table displays the specified volume in cc. Alternatively, for the relative volume format, the fourth column of the table presents the specified volume in percent. For either the absolute or relative volume constraints, the fifth column of the table shows the corresponding dose tolerance limit in Gy. In contrast to the volume-dose limits, some of the dose limits are posed in terms of the maximum allowed point dose, and these are located in column six. No dose limit has an entry in both columns five and six; they are mutually exclusive. Column seven provides all references we found that mention the dose limit, and some brief notes are occasionally mentioned in the last column.

Columns eight through ten list adverse events that were reported in the literature. Column eight lists the number of adverse events (AE) reported at the dose level. The focus in this manuscript is Common Terminology Criteria for Adverse Events (CTCAE)16 Grade 3 events or higher, although some Grade 2 adverse events are also recorded in column eight. Column nine lists how many patients received the relevant dose range to the corresponding critical anatomical structure. Column ten lists how many patients were enrolled in the study. Columns eight and nine show that some of the dose tolerance limits presented in Table 1 are associated with a high percentage of AE and should be avoided.

Some of the dose tolerance limits for kidney, liver and lung are posed in terms of a critical volume instead of an allowed volume. This means that instead of allowing a certain small volume of a critical structure to exceed a particular dose, the requirement is that a certain critical volume of the structure must be spared, remaining below the specified dose. In the notes in Table 1 we write “must be spared” to denote these instances.

Some of the dose tolerance limits in Table 1 are for one to five fractions of high-dose radiation following a course of conventionally fractionated radiation, such as the 23 Gy in five fraction bladder limit from RTOG 0417. In general, the topic of retreatment is beyond the scope of this manuscript, and most of this type of limit comes from high dose radiation (HDR) brachytherapy treatments rather than SBRT, but some researchers have used this conceptually to consider what could be achievable in a retreatment setting.

It must be noted that dose tolerance limits and dose-volume histogram (DVH) analysis only show part of the overall situation. The location where the high dose occurred could sometimes be more important than how high the dose is. For example, with the steep dose gradients achievable with stereotactic delivery systems it would be possible to cover the entire cross-sectional area of the spinal cord with a high dose, yet still only exceed the dose tolerance limit in one or two cc. In particular, the 8 cc spinal cord dose tolerance limits from Chang and Timmerman6 should be used with caution. Timmerman’s more recent very thorough update8 now presents spinal cord volume-dose limits in terms of 0.25 cc and 1.2 cc volumes, instead of the previous 8 cc volume. In general, circumferential irradiation of any critical structure should be avoided whenever possible.
| Organ                      | # fx | Vol. cc | % Vol. | Max Limit (Gy) | Refs. | # pts rx this in study | # pts in ≥G3 | Notes                                                                 |
|---------------------------|------|---------|--------|----------------|-------|------------------------|-------------|-----------------------------------------------------------------------|
| Aorta and Major Vessels   | 1    | 0.035   | 37     | 37             | 24    |                        |             | RTOG 0631, Limit is for ‘Great Vessels’                               |
|                           | 1    | 10      | 31     | 37             | 8,25  |                        |             | RTOG 0915, Limit is for ‘Great Vessels’                               |
|                           | 3    | 45      | 8      | 8              | 8     |                        |             | RTOG 0631 & 0915, Limit is for ‘Great Vessels’                         |
|                           | 3    | 10      | 39     | 8              | 8     |                        |             | Limit is for ‘Great Vessels’                                          |
|                           | 3    | 5       | 21     | 8              | 26    |                        |             | Limit is for Aorta                                                    |
|                           | 4    | 50      | 27     |                |       |                        |             | RTOG 0915, Limit is for ‘Great Vessels’                               |
|                           | 4    | 49      | 25     |                |       |                        |             | RTOG 0915, Limit is for ‘Great Vessels’                               |
|                           | 4    | 10      | 43     | 37             | 25    |                        |             | Limit is for ‘Great Vessels’                                          |
|                           | 4    | 1       | 40     | 27             | 27,28 |                        |             | Limit is for ‘Major Vessels’                                          |
|                           | 4    | 10      | 35     | 27             | 27,28 |                        |             | Limit is for ‘Major Vessels’                                          |
|                           | 4    | 47.2    | 15     | 27             | 29,30 |                        |             | Limit is for Pulmonary artery                                         |
|                           | 5    | 53      | 8      |                |       |                        |             | Limit is for ‘Great Vessels’                                          |
|                           | 5    | 52.5    | 31     |                |       |                        |             | RTOG 0813, QOD, Limit is for ‘Great Vessels’                           |
|                           | 5    | 10      | 47     |                |       |                        |             | RTOG 0813, QOD, Limit is for ‘Great Vessels’                           |
| Area Post-rema            | 1    | 6.2     | 32,33  |                |       |                        |             | Use anti-nausea medication                                            |
|                           | 1    | 15      | 8.7    | 8              |       |                        |             | Limit is for bladder wall                                             |
|                           | 1    | 10      | 8      |                |       |                        |             | Limit is for bladder wall                                             |
|                           | 2    | 1       | 14.25  | 30             | 35    |                        |             | RTOG 0321, Limit is for bladder wall                                  |
|                           | 3    | 1       | 15      |                |       |                        |             | Limit is for bladder wall                                             |
|                           | 3    | 15      | 15     |                |       |                        |             | Limit is for bladder wall                                             |
|                           | 4    | 10%     | 41.8   |                |       |                        |             | RTOG 9708, after 45Gy conventional                                     |
| Bladder                   | 4    | 10      | 37.5   |                |       |                        |             | Limit is for bladder wall                                             |
|                           | 4    | 5       | 36     |                |       |                        |             | Limit is for bladder wall                                             |
|                           | 5    | 10      | 37     |                |       |                        |             | Limit is for bladder wall                                             |
|                           | 5    | 15      | 18.3   |                |       |                        |             | Limit is for bladder wall                                             |
|                           | 5    | 5       | 38     |                |       |                        |             | Limit is for bladder wall                                             |
|                           | 5    | 10      | 40     |                |       |                        |             | RTOG 0116, after 45Gy conventional                                     |
|                           | 5    | 15      | 41     |                |       |                        |             | RTOG 0117, after 45Gy conventional                                     |
|                           | 5    | 5       | 42     |                |       |                        |             | RTOG 0118, after 45Gy conventional                                     |
|                           | 5    | 10      | 43     |                |       |                        |             | RTOG 0118, after 45Gy/25fx, Section 6.2.3.8                            |
|                           | 5    | 15      | 44     |                |       |                        |             | RTOG 0118, after 45Gy/25fx, Appendix VIII                              |
| Organ                  | # | Vol. | Vol. | Vol. Limit | Max Limit | #AE | # pts rx this dose | # pts in study | Notes                                                                 |
|------------------------|---|------|------|------------|-----------|-----|--------------------|----------------|-----------------------------------------------------------------------|
| Bone: Femoral head     | 1 | 10   |      | 14         | 8         |     |                    |                | RTOG 0915                                                            |
|                        | 3 | 10   | 21.9 | 10         | 8         |     |                    |                | 25 months after SBRT                                                 |
|                        | 5 | 10   | 30   | 1           | 8         |     |                    |                | 17 pain, 5 fractures                                                  |
| Bone: Rib Cage         | 1 | 10   | 30   | 25         | 25        |     |                    |                | RTOG 0915                                                            |
|                        | 3 | 10   | 60   | 17         | 60        |     |                    |                | ML estimate of 50% risk                                              |
|                        | 3 | 2    | 49.8 | 7          | 3.5       | 33  |                    |                | 17 pain, 5 fractures                                                  |
|                        | 3 | 2.9  | 46.4 | 7          | 3.5       | 33  |                    |                | ML estimate of 50% risk                                              |
|                        | 3 | 5.5  | 36.4 | 7          | 3.5       | 33  |                    |                | ML estimate of 50% risk                                              |
| Bone: TMJ              | 5 | 10   | 35   | 28         | 3         | 27  |                    |                | RTOG 0915                                                            |
| Bowel                  | 1 | 5%   | 20   | 1          | 77        |     |                    |                | 17 pain, 5 fractures                                                  |
|                        | 1 | 5%   | 21   | 3          | 18        |     |                    |                | 17 pain, 5 fractures                                                  |
|                        | 1 | 8    | 8    | 34         |           |     |                    |                | RTOG 0915                                                            |
| Bowel                  | 1 | 5    | 30   | 41         |           |     |                    |                | G4 small bowel perforation                                           |
|                        | 1 | 1    | 25   | 32         |           |     |                    |                | G4 small bowel perforation                                           |
| Bowel: Colon           | 1 | 5    | 14.3 | 24         |           |     |                    |                | RTOG 0631                                                            |
|                        | 1 | 0.035| 18.4 | 24         |           |     |                    |                | RTOG 0631                                                            |
|                        | 1 | 22   | 22   | 8          |           |     |                    |                |                                                                       |
|                        | 1 | 11   | 11   | 8          |           |     |                    |                |                                                                       |
|                        | 3 | 30   | 30   | 8          |           |     |                    |                |                                                                       |
| Organ      | #  | Vol. | Vol. | Vol. | Max. | Max. | #AE | # pts | # pts |
|------------|----|------|------|------|------|------|-----|------|------|
|            | # fx | # cc | %    | Limit (Gy) | Limit (Gy) | Refs. | ≥G3 dose | in study |
| Bowel: Colon (cont’d.) | 1   | 5%   | 22.5 | 18,39,50,53 | 2 | 16 | After 4-10 months, G3-4 ulceration encountered |
|            | 1   | 5%   | 22.5 | 50 | 1 | 77 | RTOG 0631 |
|            | 1   | 5%   | 22.5 | 16 | 24 | 8 | RTOG 0631 |
|            | 0.035 | 16 | 24 | 24 | 24 | 8 | RTOG 0631 |
| Bowel: Duodenum | 1   | 50%  | 12.5 | 18,39,53 | 2 | 16 | After 4-10 months, G3-4 ulceration encountered |
|            | 1   | 50%  | 12.5 | 19,50 | 2 | 16 | After 4-10 months, G3-4 ulceration encountered |
|            | 1   | 50%  | 12.5 | 18,39,53 | 2 | 16 | After 4-10 months, G3-4 ulceration encountered |
| Bowel: Ileum | 6   | 0.5% | 11.9 | 24 | 24 | RTOG 0631 |
|            | 1   | 0.035 | 15.4 | 24 | 24 | RTOG 0631 |
|            | 1 | 19 | 8 | 8 | 8 | RTOG 0631 |
|            | 1 | 5 | 9.8 | 9.8 | 9.8 | RTOG 0631 |
|            | 3 | 10 | 16.2 | 6 | 6 | 8 | RTOG 0631 |
| Bowel: Jejunum | 3   | 5 | 16.2 | 8 | 8 | 8 | RTOG 0631 |
|            | 5 | 10 | 19.5 | 6 | 6 | 8 | RTOG 0631 |
|            | 5 | 5 | 19.5 | 8 | 8 | 8 | RTOG 0631 |
|            | 5 | 35 | 8 | 8 | 8 | 8 | RTOG 0631 |
|            | 5 | 29 | 6 | 6 | 6 | 6 | RTOG 0631 |

Limit is for sigmoid colon
RTOG 0118, after 45Gy conventional
RTOG 0631
RTOG 0631
RTOG 0631
RTOG 0631
RTOG 0631
RTOG 0631
RTOG 0631
| Vol. | # pts | Vol. | Vol. | # pts | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. | Vol. |Vol.
| Organ                | # fx | Vol. cc | Vol. % | Vol. Limit (Gy) | Max Limit (Gy) | Refs. | #AE rx this dose | # pts in study | Notes                                                                 |
|----------------------|------|---------|--------|-----------------|----------------|-------|------------------|----------------|-----------------------------------------------------------------------|
|                      | 1    |         |        |                 | 12             |       | ≥G3              |                | RTOG 9708, after 45Gy conventional                                     |
| Bowel: Small Intestine| 3    | 5       | 21     |                 |                |       |                  |                |                                                                       |
|                      | 3    | 10      | 21     |                 | 54             |       |                  |                |                                                                       |
|                      | 6    | 0.5     | 30     |                 | 56             |       |                  |                |                                                                       |
|                      | 1    |         | 5%     | 22.5            | 53             |       |                  |                | 50% isodose line should not reach distal wall                          |
|                      | 1    |         | 4%     | 22.5            | 50             |       |                  |                |                                                                       |
|                      | 1    |         | 50%    | 14.5            | 53             |       |                  |                |                                                                       |
|                      | 1    | 10      | 11.2   |                 | 24             |       |                  |                |                                                                       |
|                      | 1    | 0.035   | 16     |                 | 24             |       |                  |                |                                                                       |
|                      | 1    |         | 1       | 12.4            | 25             |       |                  |                |                                                                       |
|                      | 1    | 10      | 13     |                 | 25             |       |                  |                |                                                                       |
|                      | 1    | 10      | 11.2   |                 | 25             |       |                  |                |                                                                       |
|                      | 1    |         | 1       | 53,60           | 25             |       |                  |                |                                                                       |
|                      | 3    | 5       | 21     |                 | 26,54,55,56    |       |                  |                |                                                                       |
| Bowel: Stomach       | 3    | 10      | 15     |                 | 8              |       |                  |                |                                                                       |
|                      | 3    | 10      | 21     |                 | 8              |       |                  |                |                                                                       |
|                      | 3    | 10      | 21     |                 | 18,25          |       |                  |                |                                                                       |
|                      | 4    | 10      | 17.6   |                 | 25             |       |                  |                |                                                                       |
|                      | 5    | 10      | 28     |                 | 25             |       |                  |                |                                                                       |
|                      | 5    | 10      | 18.3   |                 | 25             |       |                  |                |                                                                       |
|                      | 5    | 1       | 25.5   |                 | 25             |       |                  |                |                                                                       |
|                      | 6    | 0.5     | 30     |                 | 48             |       |                  |                |                                                                       |
|                      | 6    |         | 0.5    | 30              | 57             |       |                  |                |                                                                       |

Brachial Plexus: Ipsilat.

| #        | Vol. cc | Vol. % | Vol. Limit (Gy) | Max Limit (Gy) | Refs. | #AE rx this dose | # pts in study | Notes                                                                 |
|----------|---------|--------|-----------------|----------------|-------|------------------|----------------|-----------------------------------------------------------------------|
| 1        | 5       | 14.4   |                 | 24             |       |                  |                | RTOG 0631, limit is for sacral plexus                                |
| 1        | 0.035   | 18     |                 | 24             |       |                  |                | RTOG 0631, limit is for sacral plexus                                |
| 1        | 5       | 14     |                 | 24             |       |                  |                | RTOG 0631, limit is for sacral plexus                                |
| 1        | 0.035   | 17.5   |                 | 24             |       |                  |                | RTOG 0631, limit is for sacral plexus                                |
| Organ                     | # fx | Vol. Limit (Gy) | Vol. % | # Vol. Limit (Gy) | Max Limit (Gy) | Refs. | #AE ≥G3 | # pts rx this dose | # pts in study | Notes |
|---------------------------|------|----------------|--------|------------------|---------------|-------|---------|-------------------|----------------|-------|
| Brain                     | 5    | 100%           | 20     | 15               | 8             |       |         |                   |                | RTOG 7361 for palliative whole brain |
| Brain-stem                | 1    | 10             | 8      | 10               | 7             |       |         |                   | 1              | Preferred when possible |
| Brain-stem                | 1    | 0.5            | 7      | 7                | 7             |       |         |                   | 1              | Preferred when possible |
| Brain-stem                | 1    | 18             | 8      | 18               | 8             |       |         |                   | 1              | Preferred when possible |
| Brain-stem                | 5    | 1              | 8      | 1                | 8             |       |         |                   | 5              | Preferred when possible |
| Brain-stem                | 5    | 100%           | 20     | 100%             | 20            |       |         |                   | 5              | Preferred when possible |
| Bronchi                   | 1    | 22.11          | 8      | 22               | 8             |       |         | 1                 | 1              | 114               |
| Bronchi                   | 1    | 20.2           | 8      | 20.2             | 25            |       |         | 1                 | 1              | RTOG 0915 |
| Bronchi                   | 1    | 4              | 8      | 4                | 8             |       |         | 1                 | 1              | RTOG 0915 |
| Bronchi                   | 3    | 6,8,27,39,46,65| 30     | 6,8,27,39,46,65  | 30            |       |         | 1                 | 1              | RTOG 0618, Limit is for ipsilateral bronchus |
| Bronchi                   | 3    | 5              | 8      | 5                | 8             |       |         | 1                 | 1              | RTOG 0618, Limit is for ipsilateral bronchus |
| Bronchi                   | 3    | 20             | 8      | 20               | 68            |       |         | 1                 | 1              | RTOG 0618, Limit is for main bronchi |
| Organ          | # | Vol. | Vol. Limit | Max Limit | Refs. | #AE | # pts in study | Notes                                      |
|---------------|---|------|------------|-----------|-------|-----|----------------|--------------------------------------------|
|               | # |      |            |           |       |     |                |                                            |
|               | 3 | 4    | 15         |           |       | 8   |                |                                            |
|               | 4 |      |            |           |       | 50  |                |                                            |
|               | 4 | 1    | 40         |           |       | 27  |                |                                            |
|               | 4 | 10   | 35         |           |       | 27,28 |                |                                            |
| Bronchi (cont’d.) | 4 |      |            | 34.8      |       | 25  |                |                                            |
|               | 4 |      |            | 31.6      |       | 29,30 |                |                                            |
|               | 4 | 4    | 15.6       |           |       | 25  |                |                                            |
|               | 5 |      |            | 52.5      |       | 31  |                |                                            |
|               | 5 | 4    | 45         |           |       | 69  | 1 1 1          | Severe late bronchial effect               |
|               | 5 | 5    | 38         |           |       | 8   |                | Limit is for ipsilateral bronchus         |
|               | 5 | 4    | 18         |           |       | 8,31 |                |                                            |
| Cauda Equina | 1 | 5    | 14         |           |       | 24  |                |                                            |
|               | 1 | 0.035| 16         |           |       | 24  |                | RTOG 0631                                 |
|               | 1 |      |            | 17        |       | 70  |                |                                            |
|               | 1 | 16   |           |           |       | 8   |                |                                            |
|               | 1 | 5    | 14         |           |       | 8   |                |                                            |
|               | 1 | 2.9  | 8          |           |       | 70  |                |                                            |
|               | 1 | 1    | 8          |           |       | 34  |                |                                            |
|               | 1 | 15.6 |           |           |       | 71  |                | Highest allowed value; a goal was not stated |
|               | 3 | 24.2 | 7          |           |       |     |                | Median doses quoted, not limits            |
|               | 3 | 24   | 8          |           |       |     |                |                                            |
|               | 3 | 5    | 21.9       |           |       | 8   |                | Median doses quoted, not limits            |
|               | 3 | 0.1  | 18.5       |           |       | 7   |                |                                            |
|               | 3 | 1    | 10.7       |           |       | 7   |                | Median doses quoted, not limits            |
|               | 3 | 2    | 8.9        |           |       | 7   |                | Median doses quoted, not limits            |
|               | 3 | 5    | 6.2        |           |       | 7   |                | Median doses quoted, not limits            |
|               | 5 | 34   | 8          |           |       |     |                |                                            |
|               | 5 | 5    | 30         |           |       | 8   |                |                                            |
| Chiasma       | 1 |      |            | 15        |       | 17  | 7 9 50         | 77.8% chance of RON above 15Gy             |
|               | 1 |      |            | 13        |       | 72  |                |                                            |
|               | 1 |      |            | 12        |       | 73  |                |                                            |
|               | 1 |      |            |           |       | 74  |                |                                            |
|               | 1 | 10   | 8,17,72,75 |           |       | 4   | 15 50         | 7% chance of RON above this, 1.1% chance below |
|               | 1 | 0.2  | 8          |           |       | 8   |                | No RON below 10Gy, 27% RON from 10-15Gy    |
|               | 1 |      |            |           |       | 8   |                |                                            |
|               | 1 | 8    | 72,73,76   |           |       | 8   |                |                                            |
|               | 3 | 19.5 |           |           |       | 8   |                |                                            |
|               | 3 | 0.2  | 15         |           |       | 8   |                |                                            |
| Organ          | # fx | Vol. cc | Vol. % | Vol. Limit (Gy) | Max Limit (Gy) | Refs. | # pts ≥G3 | # pts rx this dose in study | Notes                                                                 |
|---------------|------|---------|--------|----------------|----------------|-------|----------|-----------------------------|---------------------------------------------------------------------|
| Chiasma (cont’d.) | 5    | 0.2     |        | 20             | 25             | 8,72,77,78 | RTOG 7361 for palliative whole brain |
|               | 5    | 100%    |        | 20             | 15             | 1      |          |                             |                                                                      |
| Cranial Nerves | 1    |         |        | 30             | 17             | 3rd, 4th, and 6th cranial nerves |
| Ears: Cochlea | 1    |         |        | 12             | 8              | 5th cranial nerve |
|               | 3    |         |        | 20             | 8              |         |          |                             |                                                                      |
|               | 5    |         |        | 27.5           | 8              |         |          |                             |                                                                      |
| Esophagus     | 3    |         |        | 27             | 6,8,27,39,45, 46,53,64,65 | RTOG 0618 |
|               | 3    |         |        | 24             | 53             |         |          |                             |                                                                      |
|               | 3    |         |        | 21             | 16.2           | RTOG 0915 |
|               | 3    |         |        | 5              | 6              | RTOG 0915 |
|               | 3    |         |        | 10             | 6              | RTOG 0915 |
|               | 4    |         |        | 1              | 35             |         |          |                             |                                                                      |
|               | 4    |         |        | 10             | 30             |         |          |                             |                                                                      |
|               | 4    |         |        | 5              | 18.8           |         |          |                             |                                                                      |
|               | 4    |         |        | 20             | 29.30          |         |          |                             |                                                                      |
|               | 5    |         |        | 52.5           | 31             | RTOG 0813, QOD |
|               | 5    |         |        | 35             | 8              |         |          |                             |                                                                      |
|               | 5    |         |        | 5              | 27.5           |         |          |                             | RTOG 0813, QOD, "non-adjacent wall"                               |
|               | 5    |         |        | 10             | 19.5           |         |          |                             |                                                                      |
| Organ       | # fx | Vol. cc | Vol. % | Vol. Limit (Gy) | Max Limit (Gy) | #AE ≥G3 | # pts rx this dose | # pts in study | Notes                              |
|-------------|------|---------|--------|----------------|----------------|---------|-------------------|----------------|-----------------------------------|
| Esophagus (cont'd.) | 5    | 1       | 25     | 29             | 29             | 6       | 6                 |                |                                   |
|             | 5    | 0.5     | 30     | 29             | 29             | 52      | 52                |                |                                   |
| Eyes: Lens  | 1    |         |        | 3              | 3              |         |                   | 39             | Preferred cumulative max          |
|             | 1    |         |        | 2              | 2              |         |                   | 79             |                                   |
|             | 2    |         |        | 6              | 6              |         |                   | 39             |                                   |
| Eyes: Retina| 3    |         |        | 3              | 3              |         |                   | 39             | Preferred cumulative max          |
|             | 3    |         |        | 7              | 7              |         |                   | 39             | Preferred cumulative max          |
|             | 5    |         |        | 3              | 3              |         |                   | 39             | Preferred cumulative max          |
| Heart       | 1    | 15      | 16     | 22             | 8,24,25        | 8       | 8,24,25           | RTOG 0631 & 0915, heart/pericardium |
|             | 3    | 15      | 24     | 8              |               | 8       | 8                 | RTOG 0631 & 0915, heart/pericardium |
|             | 3    | 5       | 21     | 26,54,55       |               | 39      | 26,54,55          | RTOG 0618       |
|             | 3    |         |        | 30             | 6,8,27,39,46, 53,61,64,65 | 39      | 26,54,55          | RTOG 0618       |
|             | 3    |         |        | 20             | 68             | 39      | 68                | RTOG 0618       |
|             | 4    |         |        | 50             | 27             | 39      | 27                | RTOG 0618       |
|             | 4    | 1       | 40     | 27,28          |               | 40      | 27,28             | RTOG 0618       |
|             | 4    | 10      | 35     | 27,28          |               | 35      | 27,28             | RTOG 0618       |
|             | 4    |         |        | 42.4           | 29,30          | 42.4    | 29,30             | RTOG 0618       |
|             | 4    | 34      |        | 25             | 25             | 34      | 25                | RTOG 0618       |
|             | 4    | 15      | 28     | 25             |               | 15      | 25                | RTOG 0618       |
|             | 5    | 1       | 40     | 52             |               | 1       | 52                | RTOG 0813, QOD, heart/pericardium |
|             | 5    |         |        | 38             | 8              | 5       | 8                 | RTOG 0813, QOD, heart/pericardium |
|             | 5    | 15      | 32     | 8.31           |               | 15      | 8.31              | RTOG 0813, QOD, heart/pericardium |
|             | 6    |         |        | 40             | 48,57          | 6       | 48,57             | RTOG 0813, QOD, heart/pericardium |
| Organ       | # fx | Vol. cc | Vol. % | Vol. Limit (Gy) | Max Limit (Gy) | Refs. | #AE ≥G3 | # pts rx this dose | # pts in study | Notes |
|-------------|------|---------|--------|----------------|----------------|-------|---------|-------------------|----------------|-------|
| Hilus       | 3    | 20      | 68     | 8.4            | 8,24           |       |         |                   |                |       |
|             | 1    | 200     |        | 2              | 39,80          |       |         |                   |                |       |
|             | 3    | 200     |        | 14.4           | 6              |       |         |                   |                |       |
|             | 5    | 200     |        | 17.5           | 8              |       |         |                   |                |       |
|             | 5    | 200     |        | 9.5            | 6              |       |         |                   |                |       |
| Kidney: Comb. | 1    | 200     | 100    | 8.4            | 8,24           |       |         |                   |                |       |
|             | 1    | 200     | 100    | 14.4           | 6              |       |         |                   |                |       |
|             | 5    | 200     | 100    | 17.5           | 8              |       |         |                   |                |       |
|             | 5    | 200     | 100    | 9.5            | 6              |       |         |                   |                |       |
| Kidney: Contra-lat. | 1    | 200     | 50%    | 5              | 18,39         |       |         |                   |                |       |
|             | 1    | 200     | 50%    | 1.5            | 18,39         |       |         |                   |                |       |
| Kidney: Ipsilat. | 1    | 200     | 5%     | 5.8            | 18,39         |       |         |                   |                |       |
|             | 1    | 200     | 50%    | 2              | 18,39         |       |         |                   |                |       |
|             | 3    | 130     | 75%    | 15             | 50            |       |         |                   |                |       |
|             | 3    | 130     | 33%    | 1.5            | 26,51,53,54,62,63 |     |         |                   |                |       |
|             | 3    | 130     | 33%    | 14.5           | 6             |       |         |                   |                |       |
| Lacrimal Gland | 1    | 200     | 5%     | 5              | 39            |       |         |                   |                |       |
|             | 2    | 10      | 39     |                | 39            |       |         |                   |                |       |
|             | 2    | 5       | 39     |                | 39            |       |         |                   |                |       |
|             | 3    | 15      | 39     |                | 39            |       |         |                   |                |       |
|             | 3    | 15      | 39     |                | 39            |       |         |                   |                |       |
|             | 5    | 5       | 39     |                | 39            |       |         |                   |                |       |
|             | 5    | 39     | 39     |                | 39            |       |         |                   |                |       |
| Larynx     | 1    | 0.035   | 4      | 10.5           | 24            |       |         |                   |                |       |
|             | 1    | 0.035   | 4      | 20.2           | 24            |       |         |                   |                |       |
|             | 5    | 0.035   | 4      | 20             | 24            |       |         |                   |                |       |
|             | 1    | 700     | 30%    | 9.1            | 8             |       |         |                   |                |       |
|             | 1    | 50%     | 12     | 53,60          |               |       |         |                   |                |       |
|             | 1    | 50%     | 7      | 53,60          |               |       |         |                   |                |       |
|             | 1    | 50%     | 5      | 50             |               |       |         |                   |                |       |
|             | 1    | 70%     | 2.5    | 50             |               |       |         |                   |                |       |
|             | 3    | 700     | 17.1   | 6,8            |               |       |         |                   |                |       |
|             | 3    | 700     | 15     | 26,53,62,63    |               |       |         |                   |                |       |
|             | 3    | 35%     | 15     | 62             |               |       |         |                   |                |       |
| Liver       | 1    | 700     | 30%    | 9.1            | 8             |       |         |                   |                |       |
|             | 1    | 50%     | 12     | 53,60          |               |       |         |                   |                |       |
|             | 1    | 50%     | 7      | 53,60          |               |       |         |                   |                |       |
|             | 1    | 50%     | 5      | 50             |               |       |         |                   |                |       |
|             | 1    | 70%     | 2.5    | 50             |               |       |         |                   |                |       |
|             | 3    | 700     | 17.1   | 6,8            |               |       |         |                   |                |       |
|             | 3    | 700     | 15     | 26,53,62,63    |               |       |         |                   |                |       |
|             | 3    | 35%     | 15     | 62             |               |       |         |                   |                |       |

200cc must be spared, RTOG 0631 renal cortex
Max dose to either kidney
200cc must be spared
200cc must be spared
200cc must be spared
200cc must be spared
75% of each kidney must be spared
130cc must be spared
2/3 of kidney must be spared
130cc must be spared
Preferred cumulative max
Preferred cumulative max
Preferred cumulative max
RTOG 0631, also for trachea
RTOG 0631, also for trachea
QOD, re-treat
700cc of normal liver must be spared
700cc of normal liver must be spared
700cc of normal liver must be spared
700cc of normal liver must be spared
35% of normal liver must be spared
| Organ (cont’d.) | # fx | Vol. cc | Vol. % | Vol. Limit (Gy) | Max Limit (Gy) | Refs. | # pts ≥G3 | # pts rx this dose | # pts in study | Notes |
|-----------------|------|---------|--------|----------------|----------------|-------|-----------|-------------------|----------------|-------|
| Liver           | 3    | 35%     | 24     | 53             |                |       |           |                   |                | 700cc of normal liver must be spared |
|                 | 3    | 33%     | 21     | 26,54,55,56    |                |       |           |                   |                | Limit is for mean dose, but 50% means median |
|                 | 3    | 50%     | 20     | 51             |                |       |           |                   |                | Limit is for mean dose, but 50% means median |
| Lungs           | 1    | 10%     | 20     | 66             |                |       |           |                   |                | Must spare 1500cc of normal lung, RTOG 0915 |
|                 | 1    | 1500    | 7      | 8,25           |                |       |           |                   |                | Must spare 1000cc nrml lung, RTOG 0631 & 0915 |
|                 | 1    | 1000    | 7.4    | 8,24,25        |                |       |           |                   |                | Extrapolated from (28) |
|                 | 2    | 50%     | 2.5    |                |                |       |           |                   |                | Extrapolated from (28) |
|                 | 3    | 35%     | 15     | 45             |                |       |           |                   |                | May subtract GTV |
|                 | 3    | 15%     | 15     | 45             |                |       | 1         | 38                |                | May subtract GTV |
|                 | 3    | 20%     | 20     | 27             |                |       |           |                   |                | RTOG 0618, Minor deviation |
|                 | 3    | 15%     | 20     | 39,53,64       |                |       |           |                   |                | RTOG 0618 |
|                 | 3    | 10%     | 20     | 39,53,64       |                |       |           |                   |                | 1500cc of normal lung must be spared |
|                 | 3    | 1000    | 10.5   | 8              |                |       |           |                   |                | 1000cc of normal lung must be spared |
|                 | 3    | 1000    | 11.4   | 8              |                |       |           |                   |                | May subtract GTV |
|                 | 3    | 10%     | 13     | 6              |                |       |           |                   |                | May subtract GTV |
|                 | 3    | 30%     | 10     | 27             |                |       |           |                   |                | May subtract GTV |
|                 | 3    | 50%     | 12.5   | 81             | 5  9  128      |       |           |                   |                | 50% risk of G2 RP, Extrapolated from their Table 4 |
|                 | 3    | 50%     | 8.5    | 81             | 4  28  128     |       |           |                   |                | 14% risk of G2 RP, Extrapolated from their Table 4 |
|                 | 3    | 50%     | 8      | 6              |                |       |           |                   |                | 7% risk of G2 RP, Extrapolated from their Table 4 |
|                 | 3    | 50%     | 7      | 6              |                |       |           |                   |                | May subtract GTV |
|                 | 3    | 50%     | 6      | 81             | 4  60  128     |       |           |                   |                | May subtract GTV |
|                 | 4    | 50%     | 5      | 27             |                |       |           |                   |                | 50% risk of G2 RP, Extrapolated from their Table 4 |
|                 | 4    | 20%     | 20     | 27,28          |                |       |           |                   |                | 14% risk of G2 RP, Extrapolated from their Table 4 |
|                 | 4    | 30%     | 10     | 27,28          |                |       |           |                   |                | 7% risk of G2 RP, Extrapolated from their Table 4 |
|                 | 4    | 1500    | 11.6   | 25             |                |       |           |                   |                | Must spare 1500cc of normal lung, RTOG 0915 |
|                 | 4    | 1000    | 12.4   | 25             |                |       |           |                   |                | Must spare 1000cc of normal lung, RTOG 0915 |
|                 | 4    | 50%     | 1.4    | 81             | 5  9  128      |       |           |                   |                | 50% risk of G2 RP, Extrapolated from their Table 4 |
|                 | 4    | 50%     | 9.4    | 81             | 4  28  128     |       |           |                   |                | 14% risk of G2 RP, Extrapolated from their Table 4 |
|                 | 4    | 50%     | 6.5    | 81             | 4  60  128     |       |           |                   |                | 7% risk of G2 RP, Extrapolated from their Table 4 |
|                 | 4    | 50%     | 5      | 27             |                |       |           |                   |                | May subtract GTV |
|                 | 4    | 40%     | 5      | 28             |                |       |           |                   |                | May subtract GTV |
|                 | 5    | 1500    | 12.5   | 8,31           |                |       |           |                   |                | Must spare 1500cc nrml lung, RTOG 0813, QOD |
|                 | 5    | 1000    | 13.5   | 8,31           |                |       |           |                   |                | Must spare 1000cc nrml lung, RTOG 0813, QOD |
| Organ          | # | Vol. cc | Vol. % | Vol. Limit (Gy) | Max Limit (Gy) | Refs. | #AE ≥G3 | # pts rx this dose | # pts in study | Notes                                                                 |
|---------------|---|---------|--------|-----------------|----------------|-------|---------|-------------------|---------------|-----------------------------------------------------------------------|
| Lungs (cont’d.) | 5 | 20%    | 25     | 52              |                |       |         |                   |               | Copied from (27,28)                                                   |
|               | 5 | 20%    | 20     | 52              |                |       |         |                   |               | Copied from (27,28)                                                   |
|               | 5 | 30%    | 10     | 52              | 1              | 50    |         |                   |               | Limit is for mean dose, but 50% means median                           |
|               | 5 | 8%     | 20     | 52              | 1              | 50    |         |                   |               | 50% risk of G2 RP, Extrapolated from their Table 4                      |
|               | 5 | 11%    | 15     | 52              | 1              | 50    |         |                   |               | 14% risk of G2 RP, Extrapolated from their Table 4                      |
|               | 5 | 50%    | 2.36   | 52              | 1              | 50    |         |                   |               | 7% risk of G2 RP, Extrapolated from their Table 4                      |
| Neurovas. Bundle | 5 | 20%    | 37.5   | 40              |                |       |         |                   |               | 77.8% chance of RON above 15Gy                                       |
|               | 5 | 50%    | 38     | 41              |                |       |         |                   |               | 7% chance of RON above this, 1.1% chance below                         |
|               | 1 |        |        | 15              | 17             | 9     | 50      |                   |               | No RON below 10Gy, 27% RON from 10-15Gy                              |
|               | 1 |        |        | 12              | 73             | 2     | 29      | 215               |               | tradition, dose tolerance not fully appreciated                       |
|               | 1 |        |        | 11              | 74             |       |         |                   |               | Preferred cumulative max                                              |
|               | 1 |        |        | 10              | 8,17,72,75     | 4     | 15      | 50                |               | Preferred cumulative max                                              |
|               | 1 | 0.2    | 8      | 8,72,73,76      |                |       |         |                   |               | Only based on two cases                                               |
|               | 1 | 0.03   | 10     | 82              |                |       |         |                   |               | Only based on two cases                                               |
|               | 2 | 0.03   | 10     | 83              |                |       |         |                   |               | Only based on two cases                                               |
|               | 2 | 0.03   | 15     | 83              |                |       |         |                   |               | Only based on two cases                                               |
|               | 3 | 0.2    | 15     | 83              |                |       |         |                   |               | Only based on two cases                                               |
|               | 3 | 0.5    | 10.5   | 83              |                |       |         |                   |               | Only based on two cases                                               |
|               | 3 |        |        | 15              | 83              |       |         |                   |               | Preferred cumulative max                                              |
|               | 3 |        |        | 5               | 83              |       |         |                   |               | Only based on two cases                                               |
|               | 5 | 0.03   | 25     | 83              |                |       |         |                   |               | Only based on two cases                                               |
|               | 5 | 0.2    | 20     | 83              |                |       |         |                   |               | Only based on two cases                                               |
|               | 5 | 0.05   | 20     | 83              |                |       |         |                   |               | Only based on two cases                                               |
|               | 5 | 0.5    | 12.5   | 83              |                |       |         |                   |               | Only based on two cases                                               |
| Penile Bulb   | 1 |        |        | 34              | 8              |       |         |                   |               |                                                                        |
|               | 1 | 3      | 14     | 8               |                |       |         |                   |               |                                                                        |
| Organ                  | # Vol. | Vol. % | # Vol. Limit (Gy) | Max Limit (Gy) | Vol. Limit #AE ≥G3 | # pts rx this dose | # pts in study | Notes |
|------------------------|--------|--------|-------------------|----------------|---------------------|-------------------|----------------|-------|
| Penile Bulb (cont’d.)  | 3      | 3      | 42                | 8              |                     |                   |                |       |
|                        | 3      |        | 21.9              | 8              |                     |                   |                |       |
|                        | 5      |        | 50                | 8              |                     |                   |                |       |
|                        | 5      | 50%    | 29.5              | 40,41          |                     |                   |                |       |
|                        | 5      |        | 30                | 8              |                     |                   |                |       |
| Renal Hilum            | 1      | 33%    | 10.6              | 8,24           | RTOG 0631           |                   |                |       |
|                        | 3      |        | 18.6              | 8              |                     |                   |                |       |
|                        | 5      |        | 23                | 8              |                     |                   |                |       |
| Skin                   | 1      | 0.035  | 26                | 24             | RTOG 0631           |                   |                |       |
|                        | 3      |        | 26                | 25             | RTOG 0915           |                   |                |       |
|                        | 3      |        | 16                | 8              | RTOG 0631 & 0915    |                   |                |       |
|                        | 1      | 10     | 23                | 24,25          |                     |                   |                |       |
|                        | 1      | 10     | 14.4              | 8              |                     |                   |                |       |
|                        | 3      |        | 54                | 23             | 3                   | 50                |                |       |
|                        | 3      |        | 48                | 63             | 1                   | 21                |                |       |
|                        | 3      | 35     | 27                |                |                     |                   |                |       |
|                        | 3      | 10     | 30                | 27             |                     |                   |                |       |
|                        | 3      |        | 30                | 45             | 1                   | 38                |                |       |
|                        | 3      |        | 24                | 8.64           |                     |                   |                |       |
|                        | 3      |        | 21                | 45             |                     |                   |                |       |
|                        | 3      | 10     | 22.5              | 8              |                     |                   |                |       |
|                        | 3      |        | 20                | 68             |                     |                   |                |       |
|                        | 4      | 1      | 40                | 27,28          |                     |                   |                |       |
|                        | 4      | 10     | 35                | 27,28          | 3                   | 27                |                |       |
|                        | 4      |        | 36                | 25             |                     |                   |                |       |
|                        | 4      | 10     | 33.2              | 25             |                     |                   |                |       |
|                        | 5      | 32     | 8,31              |                |                     |                   |                |       |
|                        | 5      | 10     | 30                | 8,31           |                     |                   |                |       |
| Spinal Cord            | 1      | 10%    | 10                | 7.24,85        | 1                   | 86                |                | 10% of {cord adjacent to tumor +6mm inf & sup} Lower extremity G4/5 weakness |
|                        | 1      | 10%    | 9.6               | 85             | 1                   | 86                |                | Lower extremity G4/5 weakness |
|                        | 1      | 0.9    | 8                 | 80             |                     |                   |                | Lower extremity G4/5 weakness |
|                        | 1      | 0.1    | 13.7              | 85,86          | 1                   | 86                |                | RTOG 0915 |
|                        | 1      | 14     | 7.8,25,71         | 85,86          | 1                   | 86                |                | RTOG 0915 |
|                        | 1      | 13.1   | 8,6,87            | 72             | 1                   | 72                |                | Ipsilateral hemiplegia and contralateral pain |
| Organ                        | # | Vol. Limit (Gy) | Max Limit (Gy) | Refs. | # pts ≥G3 | # pts rx this dose | # pts in study | Notes                                                                 |
|-----------------------------|---|-----------------|----------------|-------|----------|-------------------|----------------|-----------------------------------------------------------------------|
| # | #  | %               | #              |       |          |                   |                |                                                                        |
| 1 0.1 6.9 86,87 1 72         | Ipsilateral hemiplegia and contralateral pain |
| 1 | 13 | 7.70            |                |       |          |                   |                |                                                                        |
| 1 | 12 | 71              |                |       |          |                   |                |                                                                        |
| 1 0.6 86,87 1 72             | After 5 months, classic Brown-Sequard syndrome |
| 1 | 10 | 86,87           |                |       |          |                   |                |                                                                        |
| 1 | 100% 8 7,88,89 72           | RTOG 0631 & 0915 |
| 1 | 100% 10 72                  | Ref (86) reports higher doses for 2 of these 3 |
| 1 0.35 10 24,25             | Bilateral leg weakness & urinary retention |
| 1 | 10 | 8               |                |       |          |                   |                |                                                                        |
| 1 0.2 10 90                 | Bilateral leg weakness & urinary retention |
| 1 | 2.6 | 8              |                |       |          |                   |                |                                                                        |
| 1 | 1.7 | 8              |                |       |          |                   |                |                                                                        |
| 1 | 1.2 | 7              | 8,24,25        | 3 | 72     |                   |                |                                                                        |
| 1 | 100% 8 86,87 3 72          | RTOG 0631 SBRT only, RTOG 0915 |
| 1 | 0.02 | 8          | 86,87          | 3 | 72     |                   |                |                                                                        |
| 1 | 5 | 50             |                |       |          |                   |                |                                                                        |
| 2 | 0.1 | 24.7           | 86,88          | 1 |        |                   |                |                                                                        |
| 2 | 25.6 | 86,88      |                |       |          |                   |                |                                                                        |
| 3 | 0.1 | 30.9           | 86,87,90       | 1 | 55     |                   |                | Posterior column dysfunction, motor weakness                          |
| 3 | 27.8 | 86,87,90    |                |       |          |                   |                | Posterior column dysfunction, motor weakness                          |
| 3 | 8 | 16.5           | 6              | 1 | 55     |                   |                | Posterior column dysfunction, motor weakness                          |
| 3 | 1.7 | 24             | 87,90          | 1 | 55     |                   |                | Posterior column dysfunction, motor weakness                          |
| 3 | 24 | 39             |                |       |          |                   |                | For ‘extreme cases’ only                                               |
| 3 | 22 | 8              |                |       |          |                   |                |                                                                        |
| 3 | 21 | 5,67           |                |       |          |                   |                |                                                                        |
| 3 | 18.6 | 7          |                |       |          |                   |                |                                                                        |
| 3 | 0.25 | 18          | 8              |       |          |                   |                | Median doses quoted, not limits                                        |
| 3 | 0.1 | 16.3           | 7              |       |          |                   |                |                                                                        |
| 3 | 1.2 | 11.1           | 8              |       |          |                   |                |                                                                        |
| 3 | 8 | 5,67           | 7              |       |          |                   |                |                                                                        |
| 3 | 2 | 6.9            | 7              |       |          |                   |                |                                                                        |
| 3 | 5 | 4.1            | 7              |       |          |                   |                |                                                                        |
| 3 | 18 | 6,27,39,45,46  | 53,62,63,64,65 | 4 | 26,54,68 | 25               | 27             | RTOG 0618                                                             |
| 3 | 15 | 26             | 25             |       |          |                   |                |                                                                        |
| 4 | 26 | 25             | 27             |       |          |                   |                |                                                                        |
| 4 | 1 | 20             | 27,28          |       |          |                   |                |                                                                        |
| Organ       | # | Vol. | Vol. | Vol. | Max  | Max  | # AE | # pts | # pts |
|-------------|---|------|------|------|------|------|------|-------|-------|
|             |   |   % | Limit | Limit | Refs. | ≥G3  | rx this | in    |
|             |   | cc  | (Gy) | (Gy) |       | dose | study | Notes |
|             |   |     |      |      |       |      |       |       |
| Spinal Cord (cont’d.) | | | | | | | | |
|             | 4 | 0.35 | 20.8 | 25   |       |      |      |       |
|             | 4 | 1.2  | 13.6 | 25   |       |      |      |       |
|             | 4 | 10   | 1.5  | 27.28|       |      |      |       |
|             | 4 | 8.8  | 29.30|      |       |      |      |       |
|             | 5 | 30   | 8.31 |      |       |      |      |       |
|             | 5 | 1    | 25   | 52   |       |      |      |       |
|             | 5 | 8    | 20   | 6    |       |      |      |       |
|             | 5 | 0.25 | 22.5 | 8.31 |       |      |      |       |
|             | 5 | 0.5  | 13.5 | 31   |       |      |      |       |
|             | 5 | 22   | 42   | 92   |       |      |      |       |
|             | 5 | 20.4 | 7.93 |      |       |      |      |       |
|             | 5 | 1.2  | 13.5 | 8    |       |      |      |       |
|             | 5 | 10   | 94.95|      |       |      |      |       |
|             | 6 | 27   | 48.57|      |       |      |      |       |
| Trachea     | 1 | 4   | 10.5 | 24   |       |      |      |       |
|             | 1 | 0.035| 20.2 | 24   |       |      |      |       |
|             | 1 | 22   | 8    |      |       |      |      |       |
|             | 1 | 20.2 | 25   |      |       |      |      |       |
|             | 1 | 10.5 | 25   |      |       |      |      |       |
|             | 1 | 8.8  | 8    |      |       |      |      |       |
|             | 3 | 36   | 45   |      |       |      |      |       |
|             | 3 | 21   | 54.55|      |       |      |      |       |
|             | 3 | 30   | 46,53|      |       |      |      |       |
|             | 3 | 4    | 15   | 8    |       |      |      |       |
|             | 4 | 35   | 27.28|      |       |      |      |       |
|             | 4 | 30   | 27.28|      |       |      |      |       |
|             | 4 | 34.8 | 25   |      |       |      |      |       |
|             | 4 | 15.6 | 25   |      |       |      |      |       |
|             | 5 | 52.5 | 31   |      |       |      |      |       |
|             | 5 | 38   | 8    |      |       |      |      |       |
|             | 5 | 4    | 18   | 8.31 |       |      |      |       |
| Urethra     | 2 | 1    | 23.75| 35   |       |      |      |       |
|             | 4 | 10%  | 41.8 | 37   |       |      |      |       |

Notes:
- RTOG 0915
- RTOG 0618
- Median max dose
- To allow for future reirradiation
| Organ            | Vol. | Vol.     | Vol. Limit (Gy) | Max Limit (Gy) | Refs. | #AE ≥G3 | # pts rx this dose | # pts in study | Notes |
|------------------|------|----------|-----------------|----------------|-------|---------|-------------------|----------------|-------|
| Urethra (cont’d.)| 4    | 50%      | 39.9            | 47.5           | 37    | 37      | 39                | 39             |       |
|                  | 4    |          |                 | 45.6           | 37,38 |         |                   |                |       |
|                  | 5    | 20%      | 47              |                | 41    |         |                   |                |       |
IV. DISCUSSION

The Emami limits are for 1/3, 2/3 and whole structure irradiation. In contrast, most of the SBRT limits are for the maximum point dose or a small percentage of the volume. Even though large volume limits are not explicitly stated, the entire premise for SBRT is based on small targets, and SBRT usually isn’t used in cases where large volumes of critical structures would receive high dose. Therefore, in addition to the explicitly stated dose limits, SBRT clinicians need to ensure that large volumes of critical structures are not significantly exceeding conventional limits. Neglecting this constraint could result in high integral doses at ablative levels, with unknown consequences. Furthermore, small volume dose limits may be more affected by organ motion than large volume limits (e.g., the dose to 1 cc of bowel is more uncertain that the dose to 1/3 of bowel) – so integrated critical structure volumes may be advisable.

Several SBRT publications do present occurrences of Grade 5 adverse events. The CTCAE clearly categorizes Grade 5 as death for any type of adverse event. Compounding the problem, many authors don’t report the actual doses that the failed critical structure received. The maximum point dose in a plan could be double the prescription dose – or at the other extreme, the failed critical structure could have received a dose much lower than the prescribed dose.

Few authors state how many patients actually reached dose limits and among those that do, care must be taken to interpret the probability estimates correctly. For example, in one study, seven patients out of fifty experienced radiation-related optic neuropathy (RON) when they received doses of 15 Gy or higher to the chiasm or optic nerve in a single fraction. However, this does not imply a $7/50 = 14\%$ chance of adverse event because the authors state that only nine patients had chiasm or optic nerve doses exceeding 15 Gy. Therefore, the actual estimate of adverse event should be $7/9 = 78\%$, which is significantly higher.

Few authors state how many patients actually reached dose limits and among those that do, care must be taken to interpret the probability estimates correctly. For example, in one study, seven patients out of fifty experienced radiation-related optic neuropathy (RON) when they received doses of 15 Gy or higher to the chiasm or optic nerve in a single fraction. However, this does not imply a $7/50 = 14\%$ chance of adverse event because the authors state that only nine patients had chiasm or optic nerve doses exceeding 15 Gy. Therefore, the actual estimate of adverse event should be $7/9 = 78\%$, which is significantly higher. The number of patients actually receiving the stated dose is among the most important validation of dose tolerance limits, but we only have an entry in column nine of Table 1 for 4% of the limits. We hope that future trials will document more clearly how many patients received each dose limit. Furthermore, when adverse events do occur, it would be most helpful if the involved critical structure doses would be published.

Some dose limits might result in toxicity that was not reported in the original reference. For example, the single fraction dose tolerance limit of “5% duodenum allowed to exceed 22.5 Gy” from Koong et al. is higher than the five fraction dose tolerance limit of “5 cc duodenum is allowed to exceed 18.3 Gy” from Chang et al., even when radiobiological effects are not considered. Taking BED into account, assuming $\alpha/\beta = 3$, the Koong limit is about five times higher than the Chang limit. It is hard to imagine how such a higher limit could be employed without significant side effects, and yet Koong et al. state that, “at these doses, no Grade 3 or higher acute gastrointestinal toxicity was observed.” However, the Stanford group subsequently reported that two patients who were treated in accordance with their duodenal tolerance limits ultimately developed Grade 3–4 complications 8–10 months after treatment. This level of toxicity might be justified in attempts to aggressively attack a lethal disease such as pancreatic cancer that has few other options, but such high doses are probably not justified for more readily curable cases. Each physician must still carefully assess which dose limits are appropriate for each of their patients.

Historically, many dose tolerance limits were derived from computer simulations, animal studies, irradiated tissue samples in petri dishes and theoretical equations. None of these theoretically derived dose limits are directly presented in this manuscript. All the dose limits in this work have been previously published by various authors with apparently clinical intent. Several of the limits are from HDR brachytherapy, which typically is performed with significantly lower photon energy, although several authors have validated that some dose tolerance limits from HDR apply fairly well to SBRT. Gamma Knife delivery also uses photons with lower energy (about 1.25 MV) than most linear accelerator techniques (typically 6–18 MV),
although many clinical users commonly interchange dose tolerance limits from one treatment modality to another.

Targeting accuracy can significantly affect the application of dose tolerance limits. Gamma Knife is still the gold standard in radiation targeting accuracy, so to apply Gamma Knife dose tolerance limits to treatments using conventional linear accelerators that have potentially much poorer accuracy could be precarious. The CyberKnife has a submillimeter end-to-end accuracy specification, so the historical Gamma Knife dose tolerance limits should have great relevance. However, it must be cautioned that the submillimeter specification is measured only with a phantom. There is currently no means to measure accuracy to that precision in a patient, and the non-ideal geometry of each patient, in addition to organ movement and deformation, can potentially lead to larger-than-expected targeting errors if great expertise is not applied. To date, the CyberKnife is the only radiation therapy system available with live tracking of target motion – the CyberKnife actually moves with the target while the radiation beam is on.

Other technological improvements are able to improve the accuracy of conventional linear accelerators. Although the Novalis system (BrainLAB Inc., Munich, Germany) does not have a submillimeter end-to-end alignment specification, two research groups have shown that it is possible to achieve this. More recently, the SAlinac/submillimeter XKnife system has been demonstrated to achieve submillimeter end-to-end alignment accuracy on a conventional linac equipped with stereotactic cones.

Dose tolerance limits will not have their intended benefit if the dose calculation is not accurate. For example, Hoppe et al. showed that the posterior skin dose could be 80% higher than expected if the immobilization devices or couch top creates a bolus effect. Clinicians might have a false sense of security if they are relying on inaccurate dose calculations.

V. CONCLUSIONS

The majority of the initial SBRT patients had a relatively short life expectancy. This meant that short-term efficacy and safety of the techniques could be quickly established. Extending life expectancy by even a few months could statistically be verified within a few years. In this frail patient population with many other comorbid conditions, short-term adverse events would be seen fairly quickly. Therefore we would expect that with so many researchers using similar dose tolerance limits, many of these limits should be fairly accurate for short term effects.

Long-term efficacy and safety is much more difficult to determine, especially given the nature of late effects and the relative short life expectancy of many of the patient populations studied. The late effects might not occur frequently in patients that often do not live that long – but that does not imply that the corresponding dose tolerance limits are safe for patients with a much longer life expectancy. This is an area of intense interest to many researchers and these dose tolerance limits may evolve significantly over the next few years. Hopefully this manuscript will be a useful reference in this endeavor.

ACKNOWLEDGMENTS

This work is dedicated to the people who are persevering in the fight of their lives against cancer. The first author’s mother was diagnosed with stage 4 lung cancer with pleural effusion and spinal metastasis and given six weeks to live. That was five years ago and she recently celebrated yet another birthday! While it is true that she has spent some time in the wheelchair and in hospitals and various clinics around the country for every therapy imaginable, she also spent much of those years attending family reunions, going on train rides and hiking with the grandkids, joining their birthday parties, going on walks with the ladies from the church, taking a cruise, and visiting relatives and friends in 12 states by plane, train and automobile – with a
new appreciation of just what a precious gift from God every day of life is. When the doctors say “it’s over” that doesn’t always mean it’s over! For any patient who is determined to continue the fight against cancer, we are committed to providing every reasonable option available, with the best level of precision, skill and knowledge humanly possible.

REFERENCES

1. Papiez L, Timmerman R. Hypofractionation in radiation therapy and its impact. Med Phys 2008;35(1):112–18.
2. Barnett GH, Linskey ME, Adler JR, et al. Stereotactic radiosurgery – an organized neurosurgery-sanctioned definition. J Neurosurg. 2007;106(1):1–5.
3. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic radiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109–122.
4. Carey Sampson M, Katz A, Constine LS. Stereotactic body radiation therapy for extracranial oligometastases: does the sword have a double edge? Semin Radiat Oncol. 2006;16(2):67–76.
5. Elia A, Shih H, Lloeffler J. Stereotactic radiation treatment for benign meningiomas. Neuropsychiatr Dis Treat. 2007;3(4):E5.
6. Chang BK, Timmerman RD. Stereotactic body radiation therapy: a comprehensive review. J Clin Oncol. 2007;25(6):637–44.
7. Sahgal A, Larson D, Chang E. Stereotactic body radiosurgery for spinal metastases: a critical review. Int J Radiat Oncol Biol Phys. 2008;71(3):652–65.
8. Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008;18(4):215–22.
9. Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys. 1982;8(11):1981–97.
10. Dale RG. The application of the linear-quadratic dose effect equation to fractionated and protracted radiotherapy. Br J Radiol. 1985;58(690):515–28.
11. Douglas BG, Fowler JF. Fractionation schedules and a quadratic dose-effect relationship [Letter]. Br J Radiol. 1975;48(570):502–04.
12. Ellis F. Dose time and fractionation. A clinical hypothesis. Clin Radiol. 1969;20(1):1–7.
13. Withers HR, Thames HD, Peters LJ. A new isoeffect curve for change in dose per fraction. Radiother Oncol. 1983;1(2):187–91.
14. Barton M. Tables of equivalent dose in 2 Gy fractions: a simple application of the linear quadratic formula. Int J Radiat Oncol Biol Phys. 1995;31(2):371–78.
15. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980;6(1):1–9.
16. National Cancer Institute. Common Terminology Criteria for Adverse Events, version 3.0. 2006.
17. Leber KA, Bergloff J, Pendl G. Dose response of the visual pathways and cranial nerves of the cavernous sinus to stereotactic radiosurgery. J Neurosurg. 1998;88(1):43–50.
18. Koong AC, Le QT, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;58(4):1017–21.
19. Schellenberg D, Goodman KA, Lee F, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2008;72(3):678–86.
20. Rahimian J, Chen JC, Rao AA, Girvigian MR, Miller MJ, Greathouse HE. Geometrical accuracy of the Novalis stereotactic radiosurgery system for trigeminal neuralgia. J Neurosurg. 2004;101 Suppl 3:351–55.
21. Solberg TD, Goetsch SJ, Seleh MT, Melega W, Laca G, DeSalles AA. Functional stereotactic radiosurgery involving a dedicated linear accelerator and gamma unit: a comparison study. J Neurosurg. 2004;101 Suppl 3:373–80.
22. Grimm J, Grimm S, Dus I, et al. A quality assurance method with submillimeter accuracy for stereotactic linear accelerators. J Appl Clin Med Phys. 2011 [In press].
23. Hoppe BS, Laser B, Kowalski AV, et al. Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who’s at risk? Int J Radiat Oncol Biol Phys. 2008;72(5):1283–86.
24. Rhu S, Gerszten P, Yin F, et al. Phase II/III study of image-guided radiosurgery/SBRT for localized spine metastasis. Radiation Therapy Oncology Group 0631. Accessed at http://www.rtog.org
25. Videtic G, Singh A, Chang J, et al. A randomized phase II study comparing 2 stereotactic body radiation therapy (SBRT) schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Radiation Therapy Oncology Group 0915. Available from: http://www.rtog.org/members/protocols/0915/0915.pdf
26. Molinelli S, de Pooter J, Méndez Romero A, et al. Simultaneous tumour dose escalation and liver sparing in Stereotactic Body Radiation Therapy (SBRT) for liver tumours due to CTV-to-PTV margin reduction. Radiother Oncol. 2008;87(3):432–38.
27. Roth J, Chang J, Komaki R, Kress J. International randomized study to compare CyberKnife(R) stereotactic radiotherapy with surgical resection in stage I non-small cell lung cancer (STARS). Accessed at http://clinicaltrials.gov
28. Chang J, Balter P, Dong L, et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;72(4):967–71.
29. Takayama K, Nagata Y, Negoro Y, et al. Treatment planning of stereotactic radiotherapy for solitary lung tumor. Int J Radiat Oncol Biol Phys. 2005;61(5):1565–71.
30. Nagata Y, Takayama K, Matsu Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;63(5):1427–31.
31. Bezhak A, Bradley J, Gaspar L, et al. Seamless phase I/II study of stereotactic lung radiotherapy (SBRT) for early stage, centrally located, non-small cell lung cancer (NSCLC) in medically inoperable patients. Radiation Therapy Oncology Group 0813. Accessed at http://www.rtog.org
32. Loeffler JS, Siddon RL, Wen PY, Nedzi LA, Alexander E 3rd. Stereotactic radiosurgery of the brain using a standard linear accelerator: a study of early and late effects. Radiother Oncol. 1990;17(4):311–21.
33. Alexander E 3rd, Siddon RL, Loeffler JS. The acute onset of nausea and vomiting following stereotactic radiosurgery: correlation with total dose to area postrema. Surg Neurol. 1989;32(1):40–44.
34. Gersten PC, Ozhasoglu C, Burton SA, et al. CyberKnife frameless single-fraction stereotactic radiosurgery for tumors of the sacrum. Neurosurg Focus. 2003;15(2):E7.
35. Hsu IC, Shinhara K, Pouliot J, et al. Phase II trial of combined high dose rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate. Radiation Therapy Oncology Group 0321. Accessed at http://www.rtog.org
36. Greven KM, Corn BW, Burke TW. A phase II study of adjuvant postoperative irradiation combined with cisplatin/taxolchemotherapy following TAH/BSO for patients with high-risk endometrial cancer. Radiation Therapy Oncology Group 9708. Available from: http://www.rtog.org/members/protocols/97-08-97-08.pdf
37. Fuller DB, Lee C. CyberKnife radiosurgery for low & intermediate risk prostate cancer: emulating HDR brachytherapy dosimetry. 2008. Available from: http://clinicaltrials.gov/ct2/show/NCT00643617
38. Fuller DB, Naitoh J, Lee C, Hardy S, Jin H. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys. 2008;70(5):1588–97.
39. Mould RF, Schulz RA, Bucholz RD, et al. Robotic radiosurgery - Volume 1. Sunnyvale, CA: Cyberknife Society Press; 2005.
40. Fredlund J, Kaplan I, Meier R, et al. Prostate Cancer CyberKnife Consortium-PC3 A Multi-institutional Phase I Feasibility Study. 2007. Accessed at http://www.ckssociety.org
41. Meier R, Kaplan I, Sandra M. CyberKnife radiosurgery for organ-confined prostate cancer: homogenous dose distribution. 2008. Accessed at http://clinicaltrials.gov/ct2/show/NCT00643994
42. Small M, Levenback C, Iyer R, Hymes SR. CyberKnife radiosurgery for organ-confined prostate cancer: homogenous dose distribution. 2008. Accessed at http://clinicaltrials.gov/ct2/show/NCT00643994
43. Kwon JS, Schefter T, Stuhr K, et al. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. Radiation Therapy Oncology Group 0417. Accessed at http://www.rtog.org
44. Gaffney DK, Dicker AP, Miller B. A phase I/II study of cox-2 inhibitor, Celebrex™ (Celecoxib), and chemotherapy in patients with locally advanced cervical cancer. Radiation Therapy Oncology Group 0118. Accessed at http://www.rtog.org
45. Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic body radiotherapy for lung metastases. J Clin Oncol. 2009;27(10):1579–84.
46. Dunlap NE, Cai J, Biedermann GB, et al. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2009 May 8. [Epub ahead of print]
47. Pettersson N, Nyman J, Johansson KA. Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: a dose- and volume-response analysis. Radiother Oncol. 2009;91(3):360–68.
48. Dawson LA, Eccles C, Craig T. Individualized image guided iso-NTCP based liver cancer SBRT. Acta Oncol. 2006;45(7):856–64.
49. Heron DE, Ferris RL, Karamouzis M, et al. Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys. 2009;75(5):1493–500.
50. Chang DT, Schellenberg D, Shen J, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009;115(3):665–72.
51. Choi BO, Choi IB, Jang HS, et al. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer. 2008;8351.
52. Takeda A, Kuniteda E, Sanuki N, et al. Dose distribution analysis in stereotactic body radiotherapy using dynamic conformal multiplanar arc therapy. Int J Radiat Oncol Biol Phys. 2009;74(2):363–69.
53. Urschel HC, Kresi JJ, Luketich JD, Timmerman RD, eds. Treating tumors that move with respiration. Berlin: Springer-Verlag; 2007.
54. Méndez Romero A, Wunderink W, Hussain SM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I-II study. Acta Oncol. 2006;45(7):831–37.
55. Wulf J, Hadinger U, Oppitz U, Thiele W, Ness-Dourdoumas R, Flentje M. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol. 2001;177(12):645–55.
57. Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2008;26(4):657–64.

58. Martinez AA, Pataki I, Edmundson G, Sebastian E, Brubbins D, Gustafson G. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: A feasibility report. Int J Radiat Oncol Biol Phys. 2001;49(1):61–69.

59. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Preti JC Jr. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2008 Aug 26. [Epub ahead of print]

60. Herfarth KK, Debus J, Lohr F, et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol. 2001;19(1):64–70.

61. Baisden JM, Reish AG, Sheng K, Larner JM, Kavanagh BD, Read PW. Dose as a function of liver volume and planning target volume in helical tomotherapy, intensity-modulated radiation therapy-based stereotactic body radiation therapy for hepatic metastasis. Int J Radiat Oncol Biol Phys. 2006;66(2):620–25.

62. Scheffer TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2005;62(5):1371–78.

63. Kavanagh BD, Scheffer TE, Cardenes HR, et al. Interim analysis of a prospective phase I/II trial of SBRT for metastatic spine. Acta Oncol. 2006;45(7):848–55.

64. Timmerman RD, Pass H, Galvin J, et al. A phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with operable stage I/II non-small cell lung cancer. Radiation Therapy Oncology Group 0618. Available from: http://www.rtog.org/members/protocols/0618/0618.pdf.

65. Sinha B, McGarry RC. Stereotactic body radiotherapy for bilateral primary lung cancers: the Indiana University experience. Int J Radiat Oncol Biol Phys. 2006;66(4):1120–24.

66. Gomez DR, Hunt MA, Jackson A, et al. Low rate of thoracic toxicity in palliative paraspinal single-fraction stereotactic body radiation therapy. Radioter Oncol. 2009;93(3):141–18.

67. Wulf J, Haedinger U, Oppitz U, et al. Development of a streamlined, non-invasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys. 2004;60(1):186–96.

68. Koto M, Takai Y, Ogawa Y, et al. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol. 2007;85(3):429–34.

69. Uno T, Araga T, Isobe K, et al. Radiation bronchitis in lung cancer patient treated with stereotactic radiation therapy. Radiat Med. 2003;21(5):228–31.

70. Gerszten PC, Burton SA, Welch WC, et al. Single-fraction radiosurgery for the treatment of spinal breast metastases. Cancer. 2005;104(10):2244–54.

71. Yamada Y, Bilsky MH, Lovelock DM, et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys. 2008;71(2):484–90.

72. Lee M, Kalani Y, Cheshier S, Gibbs IC, Adler JR, Chang SD. Radiation therapy and CyberKnife radiosurgery in the management of cranioopharyngiomas. Neurosurg Focus. 2008;24(5):E4.

73. Stafford SL, Pollock BE, Leavitt JA, et al. A study on the radiation tolerance of the optic nerves and chiasm after stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2003;55(5):1177–81.

74. Iwai Y, Yamanaka K, Yoshioka K. Radiosurgery for nonfunctioning pituitary adenomas. Neurosurgery. 2005;56(4):699–705.

75. Romanelli P, Muacevic A, Striano S. Radiosurgery for hypothalamic hamartomas. Neurosurg Focus. 2008;24(5):E9.

76. Tishler RB, Loeffler JS, Lunsford LD, et al. Tolerance of cranial nerves of the cavernous sinus to radiosurgery. Int J Radiat Oncol Biol Phys. 1993;27(2):215–21.

77. Adler JR Jr, Gibbs IC, Pauwawepong P, Chang SD. Visual field preservation after multisession Cyberknife radiosurgery for periphereic lesions. Neurosurgery. 2006;59(2):244–54.

78. Pham CJ, Chang SD, Gibbs IC, Jones P, Heilbrun MP, Adler JR Jr. Preliminary visual field preservation after staged CyberKnife radiosurgery for periphereic lesions. Neurosurgery. 2004;54(4):799–810.

79. Muacevic A, Nentwich M, Wowra B, et al. Stereotactic body radiotherapy for benign tumors of the spine. Neurosurg. 2003;14(5):E16.

80. Borst GR, Ishikawa M, Nijkamp J, et al. Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy. Radiother Oncol. 2009;91(3):307–13.

81. Friedmann W, Buatti J, Mendenhall W. Linac radiosurgery: a practical guide. New York: Springer-Verlag; 1998.

82. Mehta VK, Lee QT, Chang SD, Cherney S, Adler JR Jr. Image guided stereotactic radiosurgery for lesions in proximity to the anterior visual pathways: a preliminary report. Technol Cancer Res Treat. 2002;1(3):173–80.

83. Romanelli P, Wowra B, Muacevic A. Multisession CyberKnife radiosurgery for optic nerve sheath meningiomas. Neurosurg Focus. 2007;23(6):E11.

84. Ryu S, Jin JY, Jin R, et al. Partial volume tolerance of the spinal cord and complications of single-dose radiosurgery. Cancer. 2007;109(3):628–36.

85. Sahgal A, Ma L, Gibbs I, et al. Spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2009 Sep 16. [Epub ahead of print]

86. Gerszten PC, Burton SA, Ozhasoglu C, McCue KJ, Quinn AE. Radiosurgery for benign intradural spinal tumors. Neurosurgery. 2008;62(4):887–95; discussion 895–96.

87. Gibbs IC, Kamerdusupaphon P, Ryu MR, et al. Image-guided robotic radiosurgery for spinal metastases. Radiother Oncol. 2007;82(2):185–90.

Journal of Applied Clinical Medical Physics, Vol. 12, No. 2, Spring 2011
89. Chang EL, Shiu AS, Mendel E, et al. Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine. 2007;7(2):151–60.
90. Dodd RL, Ryu MR, Kammerdsupaphon P, Gibbs IC, Chang SD Jr, Adler JR Jr. CyberKnife radiosurgery for benign intradural extramedullary spinal tumors. Neurosurgery. 2006;58(4):674–85; discussion 674–85.
91. Gerszten PC, Ozhasoglu C, Burton SA, et al. CyberKnife frameless stereotactic radiosurgery for spinal lesions: clinical experience in 125 cases. Neurosurgery. 2004;55(1):89–98.
92. Porceddu SV, Rosser B, Burmeister BH, et al. Hypofractionated radiotherapy for the palliation of advanced head and neck cancer in patients unsuitable for curative treatment—“Hypo Trial”. Radiother Oncol. 2007;85(3):456–62.
93. Yamada Y, Lovelock DM, Yenice KM, et al. Multifractionated image-guided and stereotactic intensity-modulated radiotherapy of paraspinal tumors: a preliminary report. Int J Radiat Oncol Biol Phys. 2005;62(1):53–61.
94. Chang E, Shiu AS, Lii MF, et al. Phase I clinical evaluation of near-simultaneous computed tomographic image-guided stereotactic body radiotherapy for spinal metastases. Int J Radiat Oncol Biol Phys. 2004;59(5):1288–94.
95. Shiu AS, Chang EL, Ye JS, et al. Near simultaneous computed tomography image-guided stereotactic spinal radiotherapy: an emerging paradigm for achieving true stereotaxy. Int J Radiat Oncol Biol Phys. 2003;57(3):605–13.